Aripiprazole (ARI) is a class IV drug of poor solubility and permeability. This study focused on improving the ARI solubility and permeability via solid dispersion technique (SDs), which was further loaded through intranasal insitu gel to target the brain directly. ARI- SDs were prepared by Solvent evaporation technique. SD9 was the optimum solid dispersion that enhanced the solubility of ARI by 6.5 folds and selected for preparation of in-situ intranasal gel using Chitosan and HPMC K15M. A 33 factorial design was utilized to optimize the percentage of drug released after 24 h, gelation time and gelation temperature. The gel formulations were investigated for pH, viscosity, drug content%, gelation time and temperature, gel strength, gel spreadability, mucoadhesive strength and percentage of drug released after 24 h. The optimized formula has achieved 93.4 ± 0.74 % release of ARI after 24 h, a gelation time of 76 s and gelation temperature of 33.2OC. The optimized formula was then investigated for ex-vivo permeation, nasal ciliotoxicity and showed a 7.5 folds permeability enhancement compared to ARI suspension without any sign of intranasal mucosal damage. In conclusion, the prepared in-situ gel of ARI would be a good alternative to oral delivery for schizophrenic patients.